Group 1: Cobalt Export Quota in Congo - The Democratic Republic of Congo (DRC) has announced a cobalt export quota, effective from October 16, aimed at strengthening resource sovereignty and signaling a shift from a surplus to a shortage in the cobalt market, leading to a systematic increase in price levels [1] - The DRC's Strategic Mineral Market Regulatory Authority stated that miners will be allowed to export slightly over 18,000 tons of cobalt for the remainder of this year, with annual export limits of 96,600 tons for 2026 and 2027, which is less than half of last year's production [1] - The quota distribution includes major companies such as Luoyang Molybdenum, which received a quota of 31,200 tons (32.3%), exceeding some prior expectations [1] Group 2: Future Cobalt Supply and Demand - Institutions predict a cobalt supply gap in the next two years, with global supply expected to be 290,000 tons in 2024 (DRC 220,000 tons + Indonesia 28,000 tons) against a demand of 185,000 tons, resulting in a surplus of 105,000 tons; by 2026, supply is projected to drop to 180,000 tons (DRC 96,600 tons + Indonesia 40,000 tons) while demand will rise to 200,000 tons, leading to a shortfall of 20,000 tons [2] Group 3: Market Trends and Stock Performance - The Nasdaq China Golden Dragon Index fell by 6.1%, with major U.S. stock indices also experiencing significant declines, indicating a bearish trend in the market [3] - Notable declines were observed in large tech stocks, with companies like Broadcom and Tesla dropping nearly 6% and 5.06% respectively, reflecting broader market challenges [3] Group 4: Rare Earth Prices - Baotou Steel and Northern Rare Earth announced an increase in rare earth concentrate prices for Q4 2025, with a projected 37.13% increase compared to Q3 [7] Group 5: Company Announcements - China Energy Construction signed three new energy EPC contracts worth approximately 27.45 billion USD (about 195.54 billion RMB) with Saudi companies [11] - Smoore International reported a record high quarterly revenue of approximately 4.1968 billion RMB, a year-on-year increase of about 27.2% [12] - Kelun-Biotech's TROP2ADC drug received approval for a new indication, expanding its market potential in treating specific lung cancer cases [13] - Zhaojin Mining reported a net profit of approximately 2.117 billion RMB for the first three quarters of 2025, a year-on-year increase of 140.43% [14]
智通港股早知道 | 刚果(金)钴出口配额落地 高通因涉嫌违反反垄断法被立案调查